DEXAMETHASONE, CYCLOPHOSPHAMIDE, VINCRISTINE SULFATE, METHOTREXATE, LEVETIRACETAM, Blinatumomab SC2, Blinatumomab SC1, CYTARABINE
20180257
Phase 2 small_molecule active
Quick answer
DEXAMETHASONE, CYCLOPHOSPHAMIDE, VINCRISTINE SULFATE, METHOTREXATE, LEVETIRACETAM, Blinatumomab SC2, Blinatumomab SC1, CYTARABINE for Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL, is a Phase 2 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Amgen Technology (Ireland) UC
- Indication
- Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL,
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active